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Abstract
Platelets are classically used in the clinic to maintain hemostasis, while recent evidence has 
shown the important role for platelets in the host inflammatory and immune responses. 
In fact, platelets in vivo produce different mediators such as cytokines or chemokines, 
which may be involved in the course of disease treatment, thus platelets transfusion is 
often an effective therapy in many cases. It is well known that platelets can regulate neu-
trophils, lymphocytes and other immune cells behavior in immune response, thus direct-
ing these immune cells onto the damaged tissues, organs or infected sites. On the other 
hand, platelets can induce neutrophil extracellular traps release in response to bacterial 
or viral infection. All the characterized novel profile of platelet, if not all, at least in some 
situations, should be take into consideration when platelets have to be transfused into 
patients.
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1. Introduction
Platelet is one of the visible components in mammalian blood and is shed from the cytoplasmic 
cleavage of megakaryocytes in bone marrow. Platelets are small and nucleuses cells with a 
diameter of 2–3 µm. There are 100–300 × 109/L platelets in human blood circulation system [1, 
2]. It was first proposed as platelets by an Italian physician Giulio Bizzozero in 1862 after he 
found that platelets played an important role in the process of hemostasis after vascular injury 
[3]. Now, platelets are used to curing dysfunction of blood coagulation, thrombopenia and 
other diseases in hemostasis. As blood homeostasis greatly depends on platelets (PLT), plate-
lets are routinely transfused and its consumption is enormous in worldwide. There approxi-
mately 393375 PLT components were administrated between 2010 and 2012 in the United States 
America [4], while the transfusion of PLT in China increases dramatically during past years.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
To prevent activation in vitro before transfusion, platelets are conventionally being main-
tained at 22 ± 2°C within shaking incubators, and this strategy only can guarantee functional 
PLT available for 5–7 days. This storage temperature for PLT is a risk because of bacterial con-
tamination. However, bacterial infections after platelet transfusion are rarely reported. There 
were only 39 transfusion-transmitted bacterial infected cases among the 790854 PLT transfu-
sions [5]. We recorded that the adverse reaction after PLT transfusion was 1% between 2013 
and 2015, and bacterial contamination was not observed at all. The main reason undoubtedly 
is restrictive PLT prepare and administrative procedures. However, the possibility that plate-
lets may have the potency to inhibit bacteria growth is not excluded.
Now, there is gradually recognized that platelets not only participate in hemostasis but 
also play a role in immune response. Actually, platelets have been reported could help liver 
macrophages (known as Kuffer cells) to fight against Bacillus cereus and methicillin-resistant 
Staphylococcus aureus (MRSA) in mice and platelets were the first cells that contacted with bac-
teria in liver [6, 7]. Platelets were also identified to contain immune recognition receptors, such 
as Toll-like receptor 4 (TLR4). Platelets are shedding from megakaryocytes in bone marrow. 
Each megakaryocyte can produce about 2000 platelets. The content of mRNA is very low in 
platelet, but it possesses 1/3 transcripts of the whole human genome can encode [8, 9]. There 
are α, δ and λ particles in platelets, and it is well known that microbicidal proteins (PMPs) 
and antibacterial effect cytokines are contained in the α particles [10]. So it’s no strange that 
platelets may have the functions similar to neutrophilic granulocyte, and behavior more like 
immune cells [11].
As methicillin-resistant S. aureus infection usually results in high mortality, it has been a seri-
ous threat to clinical patients and public health. Broad-spectrum antibiotics vancomycin, 
cefoxitin and tigecycline are used to control MRSA infection, but frequent use of antibiotics is 
easy to induce drug resistance. Thus the multidrug resistant “super bacterial” was produced. 
The “super bacterial” is a great threat to human health. Cunningham et al. found that the 
platelet-rich plasma (PRP) could significantly inhibit the growth of E. coli in vitro [12]. In vivo 
studies using rabbit endocarditis model have shown that platelet-rich plasma could distinctly 
relieve the early stage endocarditis induced by S. aureus [13]. These studies may reveal the 
antimicrobial effect of platelets, and platelets may be a potential therapeutical agent to retard 
the regeneration of “super bacterial”.
2. Platelet is essential to coagulation
The physiological role of platelets is to aggregate, be activated to adhesion and initial the 
blood clot process on the wound site. Stimulating factors such as hormones, hypoxia, vascular 
endothelial injury and a variety of proinflammatory cytokines, granules can cause platelet 
activation. When the injury of blood vessel occurs, the structure of collagen located in vascu-
lar endothelium is changed to be easily combined with von Willebrand factor (vWF). Then the 
vWF/collagen complex is recognized by the glycoprotein Ib α (GPIbα), which is expressed on 
the surface of platelets, to recruit platelets to the injured site. Meanwhile, the collagen recep-
tor glycoprotein VI (GPVI) on the platelets membrane is continuously expressed to make the 
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adhesion of platelets to the injury site more stable. After then, the activation of platelets will 
happen [14, 15]. Activation of platelets is the key step in the coagulation. This is all depended 
on the cascade amplification of platelets activation. Once the platelet is activated, its shape 
changes from discoid to pseudopodium. Meanwhile, the activated platelets release particles 
to the surrounding environment, thus concentration of adenosine diphosphate (ADP) and 
thromboxane A2 (TXA2) from the platelets particles get higher in the vicinity, and will com-
bine with the adenonucleotide receptors P2X1 and P2Y12 on the adjacent platelets to induce 
activation [2, 10, 16]. CD62p (p-selectin) is a common marker for activated platelets, and can 
be acting as a bridge between platelets and immune cells that contain P-selecting Glycoprotein 
Ligand-1 (PSGL-1) [17].
Moreover, the number of platelets is negatively related to the severity of the disease. It is 
gradually clear that platelets will be activated and helpful to recruit immune cells like neutro-
phils to the infection sites. This illustrated that platelet may be not only simple enough to clot, 
but it also plays a role in the immune response.
3. Platelets express a variety of immune recognition receptors
Platelet cell surface contains a variety of pathogens pattern recognition receptors (pattern rec-
ognition receptors, PRRs), such as the Toll-like receptor (TLR) family [18], nucleotide-binding 
oligomerization domain-like receptor (NLR) family, formyl peptide receptor (FPR) (see in 
Figure 1). These PRRs are helpful to the immune system to resist infection.
TLR is classical of key molecules in human innate immune response to pathogens. Different 
TLRs could specifically recognize specific pathogens and induce immune cells to secrete 
different cytokines, resulting in varying degrees of host defense immune response. TLR4 is 
reported to be existed in both human and mice platelets [19, 20]. TLR4 can effectively recognize 
Gram-negative bacteria lipopolysaccharide (LPS) and then contribute to acquired immune 
response. LPS can induce rapid thrombocytopenia, hypotension, and sepsis. In the LPS-
induced mouse endotoxemia model, the accumulative platelets in the lung only happened in 
TLR4 wild-type mice, not in TLR4 deficient animals. LPS could stimulate platelet secretion of 
dense and granules as indicated by ATP release and P-selectin expression, and thus enhance 
platelet activation [20, 21]. Platelets express TLR4, CD14, MD2, and MyD88 which are the LPS 
receptor-signaling complex, and the effect of LPS on platelet activation could be abolished 
by an anti-TLR4-blocking antibody or TLR4 gene knockout, suggesting that the effect of LPS 
on platelet aggregation depends on the TLR4 pathway [21]. Recent studies showed platelets 
TLR4 detected its ligands in blood and induced platelets binding to adherent neutrophils [22]. 
In addition to TLR4, TLR2 and TLR9 were also detected in platelets.
The NOD2 receptor is a cytoplasmic PRR, mainly recognizing the intracellular antigen and 
could effectively recognize the Gram-positive bacterial muramyl dipeptide (MDP) to help 
the body to play immune defense. The NOD2 receptor is mainly expressed in monocytes, 
macrophages, dendritic cells, intestinal epithelial cells, and paneth cells. But NOD2 receptor 
in human platelets was identified in recent [23]. The NOD2 receptor is necessary for platelet 
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aggregation and dense granule release induced by MDP, and the RIP2/MAPK pathway is 
involved. Different from the NOD2 receptor, there is no NOD1 receptor in the platelets.
In addition to TLR4 and NOD2 receptor, platelet membrane surface also exists formyl peptide 
receptor (FPR) [24], which plays important role in antimicrobial defense and an apoptosis-
related FAS pathway surface receptors exists in platelets too [25]. These immune recognition 
receptors provide the possibility for the platelet to participate in immune response, which 
suggests that platelets have the similar function to other immune cells.
4. Platelet granules contain special antimicrobial peptide
The platelet granule contains many molecules. Among the three type (α, δ, λ) of granules, 
nucleotides (such as ADP, ATP, and GTP), bioactive amines (histamine and serotonin) and 
bioactive ions Ca2+ are stored in the δ granules; Enzymes such as proteases and glycosidases 
are stored in the λ granules; The α granules contain the abundant molecular for hemostasis 
(for example, adhesion molecules, coagulation factors), the proteins and cytokines for anti-
bacterial activity (see in Figure 1). The α granules also have molecules such as mitogenic 
factors and protease inhibitors [26]. The molecules in platelets with antibacterial activity 
now have been classified as platelet microbicidal proteins (PMPs) and kinocidins [27]. There 
are kinocidins CXC chemokine ligand 4 (CXCL4; also known as PF-4), CCL5 (also known as 
RANTES) and CXCL7, and PMPs such as a human defensin, thymosin β4, and fibrinolytic 
products (FP-A, FP-1) isolated and identified with antibacterial activity [28]. Structural analy-
sis showed that a cationic carboxy-terminal α-helix, which is consistent with peptides that 
Figure 1. The immune receptors and factors in platelets.
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exert direct microbicidal activity. These modular N- and C-terminal regions are an antiparal-
lel β-sheet domain containing the γ-core motif, which is characteristic of all cysteine-stabilized 
host defense polypeptides in CXCL4 [29]. CCL5 and CXCL4 were detected with high secre-
tion after HIV infection [30]. Human β-defensins displayed classic antimicrobial activity and 
played a key role in the process of neutrophil extracellular trap formation [31].
Recognition of bacteria by the surface receptor on platelets can activate the platelets effectively 
and specifically, and induce the release of molecules from platelets granules. Then activation 
of different types of downstream immune cells indirectly promotes platelets to be involved in 
immune defense. Studies showed that platelets secrete different type and different doses of 
molecules when stimulated by different bacteria. When Escherichia coli and Salmonella con-
tacted with platelets, the secretion of CCL5 and PDGF were at different levels, while the level 
of CD62p and CXCL4 were no significant difference. This diversity also exists when periph-
eral blood mononuclear cells (PBMCs) exposed to the supernatant of platelets contacted with 
Minnesota Salmonella-induced secrete IL-6, IL-8, and TNFα, while the supernatant of E. coli 
stimulated platelets could not do that [32].
There are many cytokines stored in platelets granules, which the role is not clear yet in hemo-
stasis. For example, transforming growth factor-β (TGF-β), which plays unique and potent 
immunoregulatory properties, is the most stored in platelets α granules compared to that 
produced by each leukocyte lineage, including lymphocytes, macrophages, and dendritic 
cells. The content of TGFβ-1 in platelet is 40-100 times higher than those in other tissues [33, 
34]. Increased levels of TGFβ-1 in circulation are usually associated with a wide range of 
dysfunctional disorders. The level of TGFβ-1 in circulation is always elevated in Marfan syn-
drome (MFS), coronary heart disease, aortic stenosis and malignancy [35–39]. In contrast, in 
patients with autoimmune thrombocytopenia, the level of TGFβ-1 in circulation was drasti-
cally reduced and increased after treatment [40]. This observation indicates that TGFβ-1 from 
platelets plays an important role in the immune regulation in diseases. So the role of TGFβ-1 
may be helping participate in immune activities, whether TGFβ-1 has an impact on bacteria 
inhibition is not known yet.
5. Antibacterial activity of platelet rich plasma
Platelet-rich plasma (PRP) is used to inhibit bacterium growth in vitro and in vivo [12]. Study 
of PRP on knee osteoarthritis displayed significant improvement in pain with an effect last-
ing for up to 6 months [41]. E. coli was significantly inhibited in a time-dependent manner 
when platelets co-cultured with platelet rich plasma (PRP) compared to the platelet poor 
plasma (PPP). The inhibitory effects increased after co-cultured for 0.5 and 2 h by addition 
of thrombin to pre-activate platelets in PRP [13]. Studies using rabbit endocarditis model 
induced by S. aureus indicated that platelet-rich plasma could distinctly relieve the early stage 
endocarditis. In a study of antimicrobial properties of autologous PRP in controlling S. aureus 
with pressure ulcers (PrUs), which is particularly to urine and feces, resulted in increased 
colonization of wounds, local application of autologous PRP changed the “biological milieu” 
of the PrUs by its antimicrobial properties, leading to the a reduction of bacterial colonization. 
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This must be a significant association between PrUs colonization and bacteria present in local 
environment [42]. An in vitro study of antibacterial properties of PRP on five bacteria (E. coli, 
S. aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae and Streptococcus faecalis), indicated 
that both PRP and PPP inhibited bacterial growth for up to 2 h of incubation. The antimicro-
bial effect of PRP was significantly higher than that of PPP, and the inoculation concentra-
tions lower or higher, the incubation times longer or shorter are mainly depending on the 
different bacterial strain. It also indicated that PRP might supply an early protection against 
bacterial contaminations, because the inhibitory effect is already evident from the first hour of 
treatment, which may provided the possibility that physiological molecules in PRP might be 
important in the time interval required for the activation of the innate immune response [12]. 
As plasma contains antimicrobial peptides and other active substances, the inhibition effect 
are dependent on platelets or not, is not that clear yet.
6. Platelets are involved in inflammation and infection
Clinical studies have shown that bacterial infections, especially sepsis, frequently brought 
extensive platelet depletion, and the number of platelets is negatively correlated with the 
severity of the disease [43]. It is known that the sepsis caused by gram-positive bacterium 
such as Staphylococcus aureus often followed by the count reduction of platelets. And infection 
of gram-negative bacterium Helicobacter pylori can induce the immune-thrombopenia [44]. 
HIV patients are easily detected with drastic platelets number decrease, and this trend is 
more relevant to the stage of AIDS progress [45]. Similar to HIV infection, infection with 
Hepatitis C virus (HCV) also lead to the reduction of platelets [46]. It also reported plate-
lets were involved in the fungal infections, such as Aspergillus, Candida, and Cryptococcus 
[47–50]. As platelets PMPs and kinocidins display sound antibacterial activity, more and 
more evidence showed that the function of platelets relates to inflammation or infection. 
Platelets help neutrophils to initial immune defense by secreting a variety of immune associ-
ated chemotactic factors, such as β-defensins [31]. Additionally, the link between platelets 
and neutrophils depends on the combination of CD62p with P-selectin glycoprotein ligand 
1 (PSGL1; also known as CD162) molecular on neutrophils. When exposed to the foreign 
bacterium, platelets are quickly activated and adhere to the wrapped bacterium, while the 
platelet cell itself occurs intracellular and extracellular membrane rearrangement. Then the 
CD62p molecular, which rearranges to the platelet membrane surface during the activation of 
platelets, combines with its ligand PSGL1 to recruit neutrophils to reach the site of infection, 
and promote the formation of neutrophils extracellular network structure (NET) [51]. After 
that, it will release antimicrobial substances to kill the bacterium. Platelets can also recruit 
T cells or B cells (see in Figure 1) to reach the site of infection after the bacterial antigens 
presented by antigen-presenting cells (APCs) such as dendritic cells (DCs) [29, 52–54]. In 
addition, a recent study reported that there was stem-like megakaryocyte committed progen-
itors (SL-MkPs) from hematopoietic stem cells (HSCs). SL-MkPs share many features with 
multipotent HSCs and served as a lineage-restricted emergency pool inflammatory. During 
homeostasis, SL-MkPs are maintained in a primed but quiescent state, thus contributing little 
to the megakaryopoiesis in a steady state. Once the inflammation is triggered, SL-MkPs are 
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activated, resulting in megakaryocyte protein production from pre-existing transcripts, then 
the activated SL-MkPs mature into other megakaryocyte progenitors. This leads to an effi-
cient replenishment of the reduced platelets during inflammatory challenge [55].
7. PLT transfusion refractory and immune-related factors
Platelet transfusion is used in cases of very low platelet counts or coagulation dysfunction. 
The count of platelets is usually performed by a blood cell counter, while thromboela-sto-
gram (TEG) is used for the test of blood clotting function. It has been defined as thrombo-
cytopenia when platelet counts are lower than 150 × 109/L. Thrombocytopathy appears if a 
patient has functionally abnormal platelets. Both thrombocytopenia and thrombocytopathy 
can result in bleeding. Platelet transfusion is suitable for and treatment of thrombocytope-
nia or platelet dysfunction in patients after or before bleeding, and has become a variety of 
hematological with chemotherapy and effective supportive therapy for cancer of leukemia 
patients [56]. But patients in multiple blood transfusion (whole blood, erythrocyte, platelets), 
pregnancy and organ transplantation, easily produce platelet-related antibodies, resulting in 
platelet transfusion refractory (PTR). Invalid platelet transfusion refers to the patient in the 
transfusion of platelets after the platelet count did not effectively improve and the clinical 
bleeding symptoms did not improve, either. It is generally believed that patients who have 
received at least two consecutive randomized ABO blood type matched platelets have not 
achieved a suitable post-transfusion platelet count correction index (CCI) value are consid-
ered to be ineffective in platelet transfusion (PTR). At present, the clinical judgment of PTR is 
mainly the percentage of platelet recovery (PPR or PR%) and CCI [57].
The main causes of PTR can be divided into two categories, non-immune factors, and immune 
factors. Most PTRs are caused by nonimmunogenic factors, such as the quality of platelet 
products, hypersplenism, disseminated intravascular coagulation, fever, and antibiotic use. 
Immune factors include ABO blood type incompatibility, anti-HLA, HPA antibodies, autoan-
tibodies, drug antibodies, allogeneic immune factors. Platelet homologous immunity is equiv-
alent to several times the frequency of erythrocyte antibodies. Antibodies against platelet 
surface antigens, especially HLA, are the main cause of PTR [57–59]. Platelet-borne antigens 
can be divided into two major categories: one is the platelet-associated antigen, including 
HLA class I antigen, as well as ABH, MN, lewis, etc; the other is platelet-specific antigen 
(HPA), which has a unique type specificity and forms part of the platelet membrane structure. 
HLA class I antibodies are the most common immune factors that cause PTR, accounting for 
80% of all immune factors and 11.7% of all etiologies. PTR caused by HPA antibodies accounts 
for about 1.7% of all etiologies. Among the HPA types, HPA 1a antigen frequency is > 99.9% in 
the Chinese population [60, 61], and HPA 2b, 5b, 4b, 3a is not high [62], suggesting that may be 
the same kind of immune factors lead to the main impact on PTR antigen system.
The current clinical platelet transfusion is a mainly preventive infusion, which become an 
important means of treatment for thrombocytopenia patients, significantly reducing the 
mortality of patients with hematological and tumor disorders. However, the pre-procedure 
platelet transfusion was reported with a high risk of thrombosis and death. In a study of 
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more than 350 hospitalized patients undergoing an invasive procedure, the rate of throm-
bosis and death increased. Another study of pre-procedure platelet transfusions in a single 
facility of 376 patients, 19 thrombotic events were appeared up to 5%, this was 21 times 
greater than the thrombosis rate reported by the Centers of Disease Control and Prevention. 
So platelets transfusion triggers may need to be reevaluated in non-bleeding patients with 
available platelet counts [63].
8. Summary
Platelets are key factors to maintain hemostasis. Since platelets are involved in infection and 
inflammation, the immunologic and antimicrobial functions of platelets cannot be ignored 
when transfused in the clinic. The abundant molecules involved in immune recognition on 
the platelets surface, such as TLRs, NOD2, CD62p, provide the basis for platelets functional 
diversity. The functions of bacteria inhibition and performances of anti-infective defense are 
being more and more recognized. The PMPs and kinocidins from platelets are more potential 
to be acting as anti-infective agents due to the remarkable immune capability. These natural 
molecules are safer for the disease control compared to antibiotics, since antibiotics are eas-
ily developed into drug-resistance. Moreover, a better understanding of platelets function is 
helpful to use in diseases therapy. There are also many molecules produced by platelets are 
unknown, which are deserved to study in the future. In short, the impact of platelets biology 
on the clinic is profound, and deeply understanding of platelets function will undoubtedly 
benefit the transfusion medicine.
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